Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

• Status: Recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized controlled multicenter clinical trial, in which about 340 patients with newly diagnosed or prior diagnosed chronic heart will be recruited. Patients will be randomly divided into Angiotensin-Neprilysin Inhibition (ARNI) group and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) group. All-cause death, cardiac death and re-hospitalization due to heart failure will be evaluated in 1, 3, 6, 12 months after recruitment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Collaborators: Baoji Central Hospital; First Affiliated Hospital Xi'an Medical University; First Hospital of Xi'an
• Treatments: LCZ 696; Sacubitril and valsartan sodium hydrate drug combination

Criteria

Inclusion Criteria:

• Age ≥ 18

• HFrEF, defined as LVEF≤40% and New York Heart Association (NYHA) class ≥ II.

• Plasma NT-proBNP ≥ 600 pg/ml, or NT-proBNP ≥ 400 pg/ml if patients have been hospitalized for heart failure in 12 months.

• If patients have been taking ACEI/ARB at recruitment, a stable dose equivalent to at least 10mg/day of enalapril will be required.

• Volunteer for the study and sign the informed consent.

Exclusion Criteria:

• Symptomatic hypotension, systolic blood pressure < 95 mmHg at baseline.

• eGFR < 30 ml(/min*1.73m2) at baseline.

• Serum potassium > 5.4 mmol/L at baseline.

• Contraindication of ACEI or ARB.